Understanding the Role of Targets and Pathways in the Treatment of Melanoma

This CME/CE/CPE certified supplement is jointly provided by:

HSME NewlogoHSME Newlogo

JADPRO 5 Fig02

JADPRO 5 Fig03


Editorial

A Letter From the Guest Editors

Lisa A. Kottschade, APRN, MSN, CNP, and LeAnn B. Norris, PharmD, FCCP, BCPS, BCOP

Read More
Editorial

A Brighter Future for Patients With Melanoma

Lisa A. Kottschade, APRN, MSN, CNP, and LeAnn B. Norris, PharmD, FCCP, BCPS, BCOP

Read More
Review Article

Diagnosis, Evaluation, and Surgical Management of Melanoma

Brianna Hoffner, MSN, ANP-BC, AOCNP®, and Christan G. Bartsch, MSHS, PA-C, MPH

Read More
Review Article

Harnessing the Immune System in the Treatment of Melanoma

Suzanne McGettigan, MSN, CRNP, AOCN®

Read More
Review Article

BRAF/MEK Inhibition in Melanoma: An Update

Lisa A. Kottschade, APRN, MSN, CNP, and Kathleen M. Madden, RN, MSN, FNP-BC, AOCNP®, APHN

Read More
Review Article

Mutations Beyond BRAF V600

Mollie Reed, MSN, ACNP-BC

Read More
Review Article

Melanomas of Noncutaneous Origin: Diagnosis, Treatment, and Outcomes

Lisa A. Kottschade, APRN, MSN, CNP

Read More
Review Article

Supportive Care and Management of Treatment-Related Adverse Effects From Immune Checkpoint Inhibitors and Targeted Therapies in Melanoma

Krista M. Rubin, MS, FNP-BC, and Lisa A. Kottschade, APRN, MSN, CNP

Read More
Review Article

Drug-Drug Interactions in Melanoma

LeAnn B. Norris, PharmD, FCCP, BCPS, BCOP

Read More
Appendix

Appendix

Compiled by Lisa A. Kottschade, APRN, MSN, CNP

Read More
Copyright © 2010-2023 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.